Randomised, double-blind, placebo-controlled study to evaluate the effect of metformin, an AMPK activator, on cognitive measures of progression in Huntington's disease patients.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518875-73-00

Acronym

TEMET-HD

Enrollment

Registered

2024-12-11

Start date

2021-12-10

Completion date

2025-06-10

Last updated

2024-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington Disease

Brief summary

The tests that make up this subscale are the Symbol Digit Modalities Test, verbal fluency under phonetic command with the letters F, A and S, colour naming, word naming and interference in the Stroop test. The sum of the raw scores obtained makes up the UHDRS cognitive score, which is the primary endpoint of this study.

Interventions

DRUGDUMMY METFORMINE 850 mg COATED TABLETS

DRUGMetformina Galenicum 850 mg comprimidos recubiertos con película EFG

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The tests that make up this subscale are the Symbol Digit Modalities Test, verbal fluency under phonetic command with the letters F, A and S, colour naming, word naming and interference in the Stroop test. The sum of the raw scores obtained makes up the UHDRS cognitive score, which is the primary endpoint of this study.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026